



The 73rd Interim Shareholders' Newsletter

From April 1, 2025 to September 30, 2025

Securities code: 8086



Thank you for your continued support.

We are pleased to present the Interim Shareholders' Newsletter for the 73rd business year (April 1, 2025, to March 31, 2026), and kindly invite you to review the information provided.

Approximately five months have passed since the management restructuring in June. During this period, the management team and employees have worked together to strengthen the operational excellence by establishing new growth and financial strategies. This year marks the first year of our new medium-term management plan, making it a critical year for laying the foundation toward achieving our targets for FY2027. As we work toward our FY2027 targets, we will continue dedicating our efforts to enhancing corporate value so that we can serve as an essential part of the healthcare infrastructure as "A truly global comprehensive healthcare company with a spirit of *WA-gokoro*." We sincerely appreciate your continued support.

President and Representative Director Yamazaki Tsuyoshi


Consolidated Financial Highlights

Net sales

317,382 million yen

1.7% up year on year

Full year Half year (Millions of yen)




Operating profit

15,337 million yen

14.0% up year on year

Full year Half year (Millions of yen)




Ordinary profit

8,234 million yen

83.3% up year on year

Full year Half year (Millions of yen)




Profit attributable to owners of parent

5,905 million yen

—

Full year Half year (Millions of yen)




Medical-related business


Net sales **252,568** million yen

4.3% up year on year

Percentage of net sales



Net sales trends (Millions of yen)




Pharmaceutical-related business


Net sales **37,089** million yen

2.3% down year on year

Percentage of net sales



Net sales trends (Millions of yen)




PharmaPackaging business


Net sales **27,224** million yen

13.8% down year on year

Percentage of net sales



Net sales trends (Millions of yen)




Other businesses

Net sales **499** million yen

30.0% up year on year

Percentage of net sales by region



Scan for more details on the medium-term management plan



TOPICS

TOPIC 1

Conclusion of Strategic Partnership Agreement with Samsung Bioepis for Commercialization of Biosimilars in Japan

Scan for more information on our pharmaceutical business



We are pleased to announce that we have entered into a strategic partnership agreement with Samsung Bioepis Co., Ltd. (Head Office: Incheon, Korea; hereinafter “Samsung Bioepis”) for the commercialization of multiple biosimilar products including ustekinumab (reference product’s brand name: Stelara®*1).

In recent years, biopharmaceuticals have accounted for an increasingly larger share of the prescription drug market. In Japan, the government has made the optimization of healthcare costs through the adoption of biosimilars a formal policy*2, and the role of biosimilars is becoming increasingly significant. Amid these developments, through this strategic partnership, NIPRO will bring to the Japanese market high-quality biosimilars developed and manufactured by Samsung Bioepis, a globally recognized biopharmaceutical company. Samsung Bioepis will be responsible for the development, manufacture, and supply of the medicines, while NIPRO

will be responsible for commercialization of the medicines in Japan. By introducing high-quality, reliably supplied biosimilars to the market, we will contribute to expanding treatment options for patients in Japan and reducing the burden of healthcare costs.



*1 Stelara is a registered trademark of Johnson & Johnson.

*2 Basic Policy on Economic and Fiscal Management and Reform 2022, For a New Form of Capitalism — Achieving a Sustainable Economy by Harnessing Processes to Overcome Challenges to Drive Growth —

TOPIC 2

Launch of the Aperta NSE® PTA XL Balloon-Expandable Angioplasty Catheter

Scan for more information on our medical device business



The Aperta NSE® PTA XL balloon catheter (Commercial name: PTA Balloon Catheter GDM06) became available for sale in Japan as of August 2025.

This device is used to treat lower extremity arterial disease (LEAD), in which arteriosclerosis leads to stenosis or occlusion of arteries in the legs and reduces blood flow.

In 2023, we obtained insurance coverage and launched the Aperta NSE® PTA balloon catheter with a balloon length of 40 mm (Commercial name: PTA Balloon Catheter GDM05). The newly added product is available with balloon lengths of 100 mm and 150 mm, making it suitable for longer lesions in the lower extremity arteries. Together with the existing Aperta NSE® PTA balloon

catheter, this allows us to support a wider range of treatments for LEAD.



TOPIC 3

Initiation of Phase II Clinical Trial for Human Autologous Bone Marrow-Derived Mesenchymal Stem Cells “STR03” for ALS

Scan for more information on our regenerative medicine business



We have initiated a Phase II corporate clinical trial for STR03, a human autologous bone marrow-derived mesenchymal stem cell therapy, jointly developed with Sapporo Medical University (Sapporo City, Hokkaido; President: Toshihiko Yamashita), targeting the indication of amyotrophic lateral sclerosis (ALS). The first patient has already received treatment.

ALS is a progressive, intractable neurological disease in which motor neurons selectively degenerate and disappear, resulting in muscle weakness and impaired respiratory function. Although therapeutic drugs have

been approved both in Japan and overseas, no treatment has yet been established that fundamentally halts disease progression.

STR03, developed jointly with Sapporo Medical University, uses autologous bone marrow-derived mesenchymal stem cells. It is expected to help slow the progression of ALS and improve quality of life through neuroprotective and neurotrophic effects, as well as by stabilizing the blood-spinal cord barrier. This clinical trial will evaluate the safety and efficacy of STR03 for ALS and aims to establish scientific evidence for its indication.

Company Overview

(As of September 30, 2025)

Company name	NIPRO CORPORATION
Established	July 8, 1954
Capital	84,397,840,000 yen
Business outline	Manufacture and sales of medical devices, pharmaceuticals, medical glass products, etc.
Number of employees	4,750 (consolidated number of employees 39,482)
Website	https://www.nipro.co.jp/en/

Shareholder Memo

Fiscal year	From April 1 of each year to March 31 of the following year
Record date for determining shareholders	Annual General Meeting of Shareholders March 31 Year-end dividend March 31 Interim dividend September 30
Number of shares per unit	100 shares
Method of public notice	Electronic public notice https://www.nipro.co.jp/en/ In the event that it is impossible to give electronic public notice due to an accident or other unavoidable circumstances, the notice will be published in the Nihon Keizai Shimbun.
Shareholder register administrator	1-3-3, Marunouchi, Chiyoda-ku, Tokyo 100-8241, Japan Mizuho Trust & Banking Co., Ltd.
Location of administrative handling	1-3-3, Marunouchi, Chiyoda-ku, Tokyo 100-8241, Japan Mizuho Trust & Banking Co., Ltd. Head Office, Stock Transfer Agency Department

Contact point	Securities company, etc. with which you do business. In the case of a special account, the relevant branch office of the special account management institution.
Special account management institution	Mizuho Trust & Banking
Relevant branch office	Toll free 0120-288-324 (9:00-17:00 excluding Saturdays, Sundays, and national holidays)
Payment of unpaid dividends	Mizuho Trust & Banking Co., Ltd. and Mizuho Bank, Ltd.

For inquiries about the electronic provision of materials for general meeting of shareholders (request for paper delivery), please contact your securities company or the Mizuho Trust & Banking electronic provision system hotline. (For special accounts, please contact the Mizuho Trust & Banking electronic provision system hotline.) Mizuho Trust & Banking electronic provision system hotline 0120-524-324 (9:00-17:00 excluding Saturdays, Sundays, and national holidays)

Receiving dividends via bank transfer

If you choose to receive your dividends via bank transfer, the dividends will be automatically deposited into your designated account on the dividend payment start date. This eliminates the risk of losing your dividend warrant or the need to visit a Japan Post Bank branch.

To ensure that you receive your dividends safely and securely, we recommend that you designate an account for receiving dividends at a bank or a securities company. There are four ways to receive your dividends:

Stock-by-stock designation method	Dividends will be paid by transfer to your designated bank account.
Registered dividend receipt account method	Dividends for all stocks you hold will be paid to a single bank account registered in advance.
Proportional allocation method	Dividends will be paid to your securities account.
Dividend warrant method	Dividends will be received at a Japan Post Bank (head office, branch, or sub-branch nationwide) or a post office.

Except for special accounts, please contact your securities company or other relevant institution for procedures and inquiries. (For special accounts, please contact Mizuho Trust & Banking Co., Ltd., Stock Transfer Agency Department toll free: 0120-288-324)

Stock Overview

(As of September 30, 2025)

Number of authorized shares	400,000,000
Number of shares issued	171,459,479
Number of shareholders	52,123
Number of shares per unit	100 shares
Status of share acquisition rights	
1. Number of share acquisition rights	3,000
2. Type and number of target shares	Common stock 20,979,020 shares
3. Issue price of share acquisition rights	Free

Major Shareholders

Name	Number of shares held (thousands)	Shareholding ratio (%)
The Master Trust Bank of Japan, Ltd. (Trust Account)	21,343	13.04
Nippon Electric Glass Co., Ltd.	10,215	6.24
Custody Bank of Japan, Ltd. (Trust Account)	9,705	5.93
BNY GCM CLIENT ACCOUNT JPRD AC ISG (FE-AC)	6,589	4.03
JPMorgan Securities Japan Co., Ltd.	4,749	2.90
STATE STREET BANK AND TRUST COMPANY 505223	3,535	2.16
HSBC HONG KONG-TREASURY SERVICES A/C ASIAN EQUITIES DERIVATIVES	3,267	2.00
THE NOMURA TRUST AND BANKING CO., LTD. AS THE TRUSTEE OF REPURCHASE AGREEMENT MOTHER FUND	3,257	1.99
NIPRO CORPORATION Employee Stock Ownership Association	2,668	1.63
Mitsubishi UFJ Morgan Stanley Securities Co., Ltd.	2,567	1.57

(Notes) 1. The company owns 7,764,000 shares of its own stock (4.53% of the total number of shares issued), but it is excluded from the above list of major shareholders.
2. Treasury stock is not included in the calculation of shareholding ratio.

Shareholder Benefit Program

To express our sincere gratitude to our shareholders for their ongoing support, we have established a shareholder benefit program. JCB Gift Cards will be presented based on the number of shares held and the period of holding.

* For details about the continuous holding period and other information, please refer to our website.




NIPRO Official Instagram Account

The NIPRO official Instagram account is used to share various information from in and out of Japan. Please follow and like our posts!

Account information

NIPRO Group Official/
[Official] NIPRO CORPORATION

Username : [wearenipro](https://www.instagram.com/wearenipro)



Except for special accounts, please contact your securities company or other relevant institution for procedures and inquiries. (For special accounts, please contact Mizuho Trust & Banking Co., Ltd., Stock Transfer Agency Department toll free: 0120-288-324)